GHRH receptor is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-05-28. Numbers and descriptions here follow the published literature rather than marketing material.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
| Property | Value | Notes |
|---|---|---|
| Target receptor | GHRH receptor (GHRHR) | Expressed on pituitary somatotrophs |
| Primary action | Stimulates growth hormone release | Amplifies pulse size |
| Half-life, albumin-binding form | Several days as reported | Slow release from albumin complex |
| Half-life, unmodified analog | About 30 minutes in animal estimates | Cleared by proteases and filtration |
| Common analytical approach | LC-MS/MS for peptide, immunoassay for hormones | Methods answer different questions |
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
The plasma half-life or half life of elimination is the time required to eliminate 50% of the absorbed dose of a drug from an organism. Or put another way, the time that it takes for the plasma concentration to fall by half from its maximum levels.
Hazard research is published: a study finds the likelihood of receiving a dementia diagnosis varies 2-fold based on place of residence in the U.S. after adjusting for underlying sociodemographic and population dementia risk factors, indicating there to be further regional risk factors or especially worse diagnostics (16 Aug.), and a study shows of the infant and toddler foods in 10 major grocery chains, 60% failed to meet the nutritional requirements of the WHO's nutrient and promotion profile model (NPPM) (21 Aug.).
==== Gastrointestinal bleeding ==== The most common cause of iron deficiency anemia in men and post-menopausal women is gastrointestinal bleeding. There are many sources of gastrointestinal tract bleeding, including the stomach, esophagus, small intestine, and the large intestine (colon). Gastrointestinal bleeding can result from regular use of some medications, such as non-steroidal anti-inflammatory drugs (e.g. aspirin), as well as antiplatelets such as clopidogrel and anticoagulants such as warfarin; however, these are required in some patients, especially those with states causing a tendency to form blood clots. Colon cancer, which typically occurs in older individuals, is another potential cause of gastrointestinal bleeding. In addition, some bleeding disorders, such as von Willebrand disease and polycythemia vera, can cause gastrointestinal bleeding.
15 January – Denis Connaghan, 79, footballer (Celtic, St Mirren, Morton). (death announced on this date) 27 January – Stuart Gray, 50, footballer (Celtic, Reading, Rushden & Diamonds), cancer. (death announced on this date) 30 January – Ally Shewan, 83, footballer (Aberdeen) and manager (Elgin City). (death announced on this date) 4 February – Mallorca Lee, 51, DJ, producer, (Ultra-Sonic), (Public Domain). 9 February – Peter Handyside, 49, footballer (Grimsby Town, Stoke City, Barnsley). 16 February – Ian McMillan, 92, footballer (Airdrieonians, Rangers, national team). (death announced on this date) 23 February – Harry Melrose, 88, footballer (Dunfermline Athletic, Aberdeen, Berwick Rangers) and manager. (death announced on this date) 24 February – Stewart Robertson, 75, conductor. (death announced on this date) 29 February – Tiffany Scott, 32, sex offender and transgender prisoner. 7 March – Nick Sheridan, 32, Irish journalist and television presenter (News2day, Reporting Scotland, The Nine) (Death announced on this date) 14 March – Angela McCluskey, 64, Scottish singer (Wild Colonials) and songwriter ("Breathe"). 15 March – Peter Kelly, 82, Scottish actor (The Tall Guy, Welcome to Sarajevo). 18 March – Peter McAleese, 81, Scottish soldier and mercenary. 20 March – Billy Kellock, 70, Scottish footballer (Cardiff City, Peterborough United, Wolverhampton Wanderers). 29 March – Iain McChesney, 79, Scottish footballer (Queen of the South). 14 April – Vincent Friell, 64, Scottish actor (Trainspotting, Restless Natives, The Angels' Share).
=== Solid interfaces === Nano-particles can self-assemble on solid surfaces after external forces (like magnetic and electric) are applied. Templates made of microstructures, like carbon nanotubes or block polymers, can also be used to assist in self-assembly. They cause directed self-assembly (DSA), in which active sites are embedded to selectively induce nanoparticle deposition. Such templates are objects onto which different particles can be arranged into a structure with a morphology similar to that of the template. Carbon nanotubes (microstructures), single molecules, or block copolymers are common templates. Nanoparticles are often shown to self-assemble within distances of nanometers and micrometers, but block copolymer templates can be used to form well-defined self-assemblies over macroscopic distances. By incorporating active sites to the surfaces of nanotubes and polymers, the functionalization of these templates can be transformed to favor self-assembly of specified nanoparticles.
Sources: en.wikipedia.org
20 August – 2024 Ulster Unionist Party leadership election: Nominations open to elect the next leader of the Ulster Unionist Party. 21 August – 2024 Ulster Unionist Party leadership election: Doug Beattie rules himself out of running for re-election as UUP leader. 22–23 August – 2024 United Kingdom general election betting scandal: The Metropolitan Police ends its investigation into the betting scandal, saying that the offences being investigated have not met the "high bar" to prove misconduct in public office. The matter remains under investigation by the Gambling Commission. The UK government authorises the Infected Blood Compensation Authority to begin making payments to affected patients. 26 August – Keir Starmer cancels the appointment of Gwyn Jenkins as national security adviser. Questions are raised over Waheed Alli and his temporary pass to Number 10. 27 August – Keir Starmer delivers his first major speech a speech since becoming prime minister, and warns that the October budget will be "painful". The UK government cancels a £40m helicopter contract agreed by former prime minister Rishi Sunak. The UK government announces an extra £10.5m of funding to prepare for new EU border checks, with major ports receiving extra funding to prepare for the changes. The Scottish Fiscal Commission (SFC) warns the SNP government that “difficult decisions” are needed to balance its budget. 28 August – Starmer meets with German chancellor Olaf Scholz in Berlin to discuss UK–EU relations, before attending the Paralympics opening ceremony in Paris.
When inhaled, plutonium can pass into the bloodstream. Once in the bloodstream, plutonium moves throughout the body and into the bones, liver, or other body organs. Plutonium that reaches body organs generally stays in the body for decades and continues to expose the surrounding tissue to radiation and thus may cause cancer. A commonly cited quote by Ralph Nader states that a pound of plutonium dust spread into the atmosphere would be enough to kill 8 billion people. This was disputed by Bernard Cohen, an opponent of the generally accepted linear no-threshold model of radiation toxicity. Cohen estimated that one pound of plutonium could kill no more than 2 million people by inhalation, so that the toxicity of plutonium is roughly equivalent with that of nerve gas. Several populations of people who have been exposed to plutonium dust (e.g. people living down-wind of Nevada test sites, Nagasaki survivors, nuclear facility workers, and "terminally ill" patients injected with Pu in 1945–46 to study Pu metabolism) have been carefully followed and analyzed. Cohen found these studies inconsistent with high estimates of plutonium toxicity, citing cases such as Albert Stevens who survived into old age after being injected with plutonium. "There were about 25 workers from Los Alamos National Laboratory who inhaled a considerable amount of plutonium dust during 1940s; according to the hot-particle theory, each of them has a 99.5% chance of being dead from lung cancer by now, but there has not been a single lung cancer among them."
By the end of the 19th century all of the major pathways of drug metabolism had been discovered, along with the outlines of protein and fatty acid metabolism and urea synthesis. In the early decades of the 20th century, the minor components of foods in human nutrition, the vitamins, began to be isolated and synthesized. Improved laboratory techniques such as chromatography and electrophoresis led to rapid advances in physiological chemistry, which—as biochemistry—began to achieve independence from its medical origins. In the 1920s and 1930s, biochemists—led by Hans Krebs and Carl and Gerty Cori—began to work out many of the central metabolic pathways of life: the citric acid cycle, glycogenesis and glycolysis, and the synthesis of steroids and porphyrins. Between the 1930s and 1950s, Fritz Lipmann and others established the role of ATP as the universal carrier of energy in the cell, and mitochondria as the powerhouse of the cell. Such traditionally biochemical work continued to be very actively pursued throughout the 20th century and into the 21st.
During this period, the Assad government arrested numerous journalists and shut down independent press centres, in addition to tightening its censorship of the Internet. From 2011 to 2015, the last four years of the Syrian war, the freedom of movement has been most widely restricted in certain areas and on certain individuals. Restrictions vary between regions, partly because of continuous fighting in certain areas. In rebel held areas there are severe restrictions on the movement of government supporters (or people thought to be government supporters). Foreign diplomats are unable to visit a majority of Syria, and are often not allowed outside of Damascus (Syrian capital). In the areas of Jindires in Afrin, and Ras al Ayn, curfews were executed in 2012 and 2013 as rebel groups put in place a curfew of 5 pm, after which nobody could be seen in public. Then in December 2014, a travel ban was announced on Syrian men aged 18 to 42 (military age). The memorandum supposedly states that all Syrian males must have special permission to leave the country, obtained from army officials. An example of an individual travel ban is Louay Hussein, president of an opposition group in Syria (Building the Syrian State, or the BSS party), was unable to attend peace talks in Moscow in April 2015 because the government refused to rid of his lifelong travel ban, however on 26 April 2015 Hussein managed to evade his ban and flee to Spain. Also Syrian human rights defenders are having their movement restrained by being held in arbitrary arrest.
Sources: en.wikipedia.org
These results highlight the clinical translation of α-amanitin’s cell-cycle-independent mechanism, which effectively targets both proliferating tumor cells and quiescent cancer stem cells. The ATAC platform is also advancing into solid tumors. TROP2-targeted conjugates based on the hRS7 antibody achieved complete tumor eradication in patient-derived xenograft models of pancreatic cancer and triple-negative breast cancer, outperforming the approved ADC sacituzumab govitecan. In January 2026, Takeda initiated a Phase I/II clinical trial of an ATAC candidate for solid tumors.
== Mechanism of action == Barbiturates act as positive allosteric modulators and, at higher doses, as agonists of GABAA receptors. GABA is the principal inhibitory neurotransmitter in the mammalian central nervous system (CNS). Barbiturates bind to the GABAA receptor at multiple homologous transmembrane pockets located at subunit interfaces, which are binding sites distinct from GABA itself and also distinct from the benzodiazepine binding site. Like benzodiazepines, barbiturates potentiate the effect of GABA at this receptor. In addition to this GABAergic effect, barbiturates also block AMPA and kainate receptors, subtypes of ionotropic glutamate receptor. Glutamate is the principal excitatory neurotransmitter in the mammalian CNS. Taken together, the findings that barbiturates potentiate inhibitory GABAA receptors and inhibit excitatory AMPA receptors can explain the superior CNS-depressant effects of these agents to alternative GABA potentiating agents such as benzodiazepines and quinazolinones. At higher concentration, they inhibit the Ca2+-dependent release of neurotransmitters such as glutamate via an effect on P/Q-type voltage-dependent calcium channels. Barbiturates produce their pharmacological effects by increasing the duration of chloride ion channel opening at the GABAA receptor (pharmacodynamics: This increases the efficacy of GABA), whereas benzodiazepines increase the frequency of the chloride ion channel opening at the GABAA receptor (pharmacodynamics: This increases the potency of GABA).
== Structure and function == In humans, BCATs are homodimers composed of two domains, a small subunit (residues 1-170) and a large subunit (residues 182-365). These subunits are connected by a short, looping connecting region (residues 171-181). Both subunits consist of four alpha-helices and a beta-pleated sheet. Structural studies of human branched-chain amino acid aminotransferases (hBCAT) revealed that the peptide bonds in both isoforms are all trans except for the bond between residues Gly338-Pro339. The active site of the enzyme lies in the interface between the two domains. Like other transaminase enzymes (as well as many enzymes of other classes), BCATs require the cofactor pyridoxal-5'-phosphate (PLP) for activity. PLP has been found to change the conformation of aminotransferase enzymes, locking the conformation of the enzyme via a Schiff base (imine) linkage in a reaction between a lysine residue of the enzyme and the carbonyl group of the cofactor. This conformational change allows the substrates to bind to the active site pocket of the enzymes.
The reinforcing effects of most addictive drugs depend on dopamine signaling in the nucleus accumbens, the same pathway that responds to natural rewards such as food and sex. Altered dopamine neurotransmission is frequently observed following the development of an addictive state. In people and in animals that have developed an addiction, altered dopamine or opioid neurotransmission is evident in the nucleus accumbens and elsewhere in the striatum.
==== Supported on silica spheres – reduction of dyes ==== Silver nanoparticles have been synthesized on a support of inert silica spheres. The support plays virtually no role in the catalytic ability and serves as a method of preventing coalescence of the silver nanoparticles in colloidal solution. Thus, the silver nanoparticles were stabilized and it was possible to demonstrate the ability of them to serve as an electron relay for the reduction of dyes by sodium borohydride. Without the silver nanoparticle catalyst, virtually no reaction occurs between sodium borohydride and the various dyes: methylene blue, eosin, and rose bengal.
Sources: en.wikipedia.org
Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.
Typical endpoints include growth hormone pulse frequency and amplitude, together with insulin-like growth factor 1 concentration. Some protocols add body composition or metabolic markers. Interpretation depends on baseline hormonal status, which varies widely between individuals.
Most human data come from small, early-stage studies, and independent replication is limited. Short-term effects on growth hormone release are documented; longer-term outcomes are not well characterized. Open questions include changes in pituitary responsiveness after repeated exposure.
It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.